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Background. Cryptococcus is the most common cause of meningitis in human immunodeficiency virus (HIV)-infected Africans. 
Despite universal exposure, only 5%–10% of patients with HIV/acquired immune deficiency syndrome and profound CD4+ T-cell 
depletion develop disseminated cryptococcosis: host genetic factors may play a role. Prior targeted immunogenetic studies in cryp-
tococcosis have comprised few Africans.
Methods. We analyzed genome-wide single-nucleotide polymorphism (SNP) genotype data from 524 patients of African de-
scent: 243 cases (advanced HIV with cryptococcal antigenemia and/or cryptococcal meningitis) and 281 controls (advanced HIV, 
no history of cryptococcosis, negative serum cryptococcal antigen). 
Results. Six loci upstream of the colony-stimulating factor 1 (CSF1) gene, encoding macrophage colony-stimulating factor 
(M-CSF) were associated with susceptibility to cryptococcosis at P < 10–6 and remained significantly associated in a second South 
African cohort (83 cases; 128 controls). Meta-analysis of the genotyped CSF1 SNP rs1999713 showed an odds ratio for cryptococ-
cosis susceptibility of 0.53 (95% confidence interval, 0.42–0.66; P = 5.96 × 10−8). Ex vivo functional validation and transcriptomic 
studies confirmed the importance of macrophage activation by M-CSF in host defence against Cryptococcus in HIV-infected patients 
and healthy, ethnically matched controls.
Conclusions. This first genome-wide association study of susceptibility to cryptococcosis has identified novel and immuno-
logically relevant susceptibility loci, which may help define novel strategies for prevention or immunotherapy of HIV-associated 
cryptococcal meningitis.
Keywords.  Africa; Cryptococcal meningitis; genome-wide association study (GWAS); HIV; macrophage colony-stimulating 
factor (M-CSF).
The fungus Cryptococcus is a common cause of meningitis in 
people with human immunodeficiency virus (HIV)/acquired 
immune deficiency syndrome (AIDS), and it is responsible 
for 15% of all AIDS-related deaths globally [1]. Despite anti-
retroviral therapy (ART) rollout, the incidence of cryptococcal 
meningitis (CM) remains high in Africa and is estimated at 
~200 000 cases annually [1]. In Africa, outcomes of current 
therapy are poor, with acute mortality of 25%–40% even with 
optimized therapy within a randomized multicenter trial [2] 
and 70% in “real-world” settings [3].
Exposure to Cryptococcus, an environmental saprophyte, is 
universal via inhalation. A population seroprevalence survey in 
the United States showed that anticryptococcal antibodies are 
common [4]. Disseminated cryptococcal infection, manifesting 
as meningoencephalitis, usually occurs in individuals with de-
pressed cell-mediated immunity, typically presenting as an op-
portunistic infection in advanced HIV (CD4 T-cell count <100/
µL). Despite likely exposure, not all patients with advanced 
HIV develop disseminated cryptococcosis: prevalence of 
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cryptococcal antigenemia (CRAG), representing early dissem-
ination from the lungs, is approximately 6% in this population 
[1]. After treatment of both cryptococcosis and underlying 
HIV, despite comparable CD4 counts, CRAG-positive indi-
viduals have a 12-month mortality rate approximately 3 times 
greater than CRAG-negative controls [5], suggesting that addi-
tional host immune factors, beyond that reflected by the CD4 
count, may contribute to cryptococcosis susceptibility.
Host immunity to Cryptococcus neoformans, an intracellular 
pathogen, requires coordinated innate and adaptive responses, 
with phagocytosis by classically activated (M1) macrophages 
promoting robust Th1-type responses and the production of 
proinflammatory cytokines (tumor necrosis factor [TNF]-α 
and interferon [IFN]-γ) playing a central role in fungal clear-
ance and host survival [3, 6]. In apparently immunocompe-
tent hosts, several CM susceptibility determinants have been 
described, including idiopathic CD4 lymphopenia, antibodies 
to granulocyte-macrophage colony-stimulating factor (CSF) 
and IFN-γ and Fc-γ receptor, and mannose-binding lectin 
polymorphisms [3, 7, 8].
Prior immunogenetic studies performed in CM have studied 
candidate genes in small populations (n = 100–150) comprising 
few African individuals [3, 7–9]. In the only CM genetic suscep-
tibility study in HIV-positive patients, targeted sequencing of 
the Fc-γ receptor in a cohort of 164 predominantly Caucasian 
men (55 HIV-positive with CM; 54 HIV-positive and 55 HIV-
negative controls without CM) demonstrated that individuals 
homozygous for the Fc-γR3A 158V polymorphism had 20-fold 
increased odds of developing CM [9]. Despite sub-Saharan 
Africa having a high infectious disease burden, few genome-
wide association studies (GWAS) of infectious disease sus-
ceptibility have been conducted in people of African descent: 
published studies include tuberculosis [10] and malaria [11, 
12]. Specific challenges to GWAS in the African population in-
clude higher genetic diversity, low linkage disequilibrium, and 
more complex genetic structure [13], although, in the long-
term, these aspects can be exploited for fine mapping of asso-
ciation signals.
In this study, we report on the first GWAS of genetic suscep-
tibility to cryptococcosis in an HIV-infected population, using 
deoxyribonucleic acid from a discovery cohort of 524 cases 
and controls of African descent recruited in Cape Town 2005–
2014 and a validation cohort of 211 recruited in Johannesburg 
2015–2017.
METHODS
Human Cohorts
Discovery and Validation Cohort
For the discovery cohort, 243 cases were recruited as part of 4 
clinical trials (1 observational, 3 randomized) of HIV-associated 
CM and a CRAG study in ART-naive adults conducted in Cape 
Town, South Africa 2005–2014 [14–18]. Cases had dissemin-
ated cryptococcal infection and/or CM as confirmed by positive 
serum and/or CSF cryptococcal antigen and/or CSF culture. 
Two hundred eighty-one controls were recruited contempora-
neously at the same hospital and referring clinic as the cases and 
had no history of cryptococcal disease and a negative serum 
cryptococcal antigen. All cases and controls were HIV-positive 
adults (age ≥18) with nadir CD4 cell count <100/μL who were 
ART-naive or within 3 months of starting ART. The validation 
cohort included 63 cases and 128 controls with CD4 cell count 
<100/μL recruited as part of a cryptococcal antigen screening 
study in ART-naive HIV-infected adults in 2015–2017 [19] 
(Table  1). Twenty cases from a clinical trial of HIV-CM in 
Kwazulu-Natal were also included in this cohort [16].
Cryptococus-Specific Transcriptome and Functional 
Characterization Cohort
 Ribonucleic acid sequencing (RNA-seq) was performed on pe-
ripheral blood mononuclear cells (PBMCs) from healthy volun-
teers of self-identified Xhosa ethnicity recruited in Cape Town. 
The functional characterization cohort included 5 HIV-infected 
patients of diverse ethnicities recruited at St George’s Hospital, 
London, with CD4 count <200 cells/μL and not on ART within 
≤12 months. Healthy donor PBMCs used were obtained from 
leukocyte cones. Further details of experimental methods and 
computational analyses are provided in the Supplementary 
Methods.
Patient Consent Statement 
The studies were approved by ethics committees at the 
University of Cape Town, the University of Witswatersrand, and 
the London School of Hygiene of Tropical Medicine. All partici-
pants gave written informed consent. 
Genotyping and Association Analyses
Five hundred twenty-four cases and controls from the 
discovery cohort were genotyped using the Illumina 
HumanOmniExpressExome-8 v1.0 single-nucleotide 
Table 1. Age, Sex, and CD4 Count for Cases and Controls in Discovery 
and Validation Cohortsa
Discovery Cohort Controls Cases
n 218 243
Age 33 (18–66) 33 (18–62)
Sex (%F) 66% 61%
CD4 (cell/μL) 46 (23–78) 37 (16–67)
Validation Cohort   
n 128 83
Age 40 (18–76) 39 (21–68)
Sex (%F) 56% 54%
CD4 (cell/μL) 44 (1–99) 25 (1–90)
aMedian (range) shown for continuous variables.
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polymorphism (SNP) chip, an exome-based array with >700 000 
genome-wide markers and >240 000 exonic markers. Two hun-
dred eleven samples from the validation cohort were genotyped 
on the Illumina GSA beadchip GSA MD v1. Samples with a low 
call rate (≤99%) and variants with a Hardy-Weinberg equilib-
rium ≤0.00001, call rate <0.99, missingness test (GENO > 0.01), 
and minor allele frequency (MAF) <0.001 were excluded from 
further analyses. Eleven genetically divergent samples were ex-
cluded from the discovery cohort and 6 from the validation co-
hort. A  total of 245 091 variants from 513 discovery samples 
passed quality control and were analyzed. Variants were aligned 
to the 1000 Genome reference and the data were imputed using 
the Michigan Imputation server. Postimputation quality con-
trols were used to remove low-quality (r2 ≤ 0.8) imputed vari-
ants before further analyses.
The association analysis was performed, and genetic suscep-
tibility to disseminated cryptococcosis was tested using logistic 
regression. P value distribution was assessed using a Quantile-
Quantile (Q-Q) plot, and there was no inflation effect on the 
association analysis. Discovery and validation cohort-imputed 
datasets were subsequently merged, and a combined cohort as-
sociation analysis was performed on 2 686 126 variants, with 
the significance threshold set at P < 5 × 10−6. The impact of top 
SNPs on gene expression was explored using eQTL information 
from the HaploReg and Genotype Tissue Expression (GTex) 
databases (see Supplementary Methods). Information on SNP 
association with annotated genes and variants within 500  kb 
of each SNP was collated. Genes associated with SNPs with 
P < 5  × 10−3 were included in pathway enrichment and gene 
ontology analyses. At the CSF1 locus, SNP rs1999713 was hard-
called on both genotyping platforms for both cohorts, so we 
performed a meta-analysis of the discovery and validation co-
horts to negate any uncertainty from imputation, using an allele 
and fixed-effects model as the effect size, and direction was very 
similar in both the discovery and replication cohorts.
Macrophage Colony-Stimulating Factor Functional Characterization 
Experiments
The PBMCs from HIV-infected patients (n = 5) and healthy 
volunteers were pretreated with macrophage-CSF (M-CSF) or 
anti-M-CSF antibody and cocultured with C neoformans H99 
(serotype A  reference strain) for 24 hours. Cells were lysed, 
plated onto fresh SAB agar for 48 hours, and colony-forming 
units were counted. For the phagocytosis assays, PBMCs 
were pretreated as described above and then challenged with 
prelabeled heat-killed C neoformans for 24 hours at 37°C. Cells 
were then captured on a flow cytometer, and the percentage of 
cells with internalized cryptococcus were identified.
RNA Sequencing and Analyses
The PBMCs were stimulated with heat-killed C neoformans 
(multiplicity of infection = 0.1) for 24 hours. Ribonucleic acid 
was extracted, and a sequencing library was prepared and 
sequenced as described in Supplementary Methods. After 
quality-control measures, reads were mapped to the human ref-
erence genome (hg19). Reads were annotated and differentially 
expressed genes between controls and Cn-treated samples were 
identified. Genes with significant differential expression were 
used in gene ontology and pathway analyses.
Availability of Data and Materials 
The human SNP array summary datasets and raw RNA-seq 
data supporting the conclusions of this article are available on 
figshare via link https://figshare.com/s/b953f3192c77cef0be98. 
The software and detailed analyses steps we undertook are 
detailed via link https://github.com/alanmichaelpittman100/
Crypto-GWAS.
RESULTS
Genome-Wide Association Analysis
We performed a GWAS of Cryptococcus susceptibility in a dis-
covery cohort of 524 age-, gender-, and CD4 count-matched 
South African HIV-infected patients: cases with dissemin-
ated cryptococcosis (defined as positive serum CRAG and/or 
CM, n = 243) and controls (n = 281) with no cryptococcosis. 
The validation cohort comprised 83 cases and 128 controls of 
African descent (Table 1). After imputation and quality-control 
measures (Supplementary Figure 1a), ~9.2 million variants from 
240 cases and 273 controls (discovery) and 79 cases and 126 
controls (validation) were analyzed using regression analysis.
In the discovery cohort, we identified multiple loci associ-
ated with susceptibility to cryptococcosis (Figure 1a). Although 
no individual SNP passed the genome-wide significance 
threshold P < 5 × 10–8, we identified 49 SNPs with P < 10–5 as-
sociated with cryptococcosis (Table  2). Six of the top suscep-
tibility SNPs (P < 7.54  × 10–6; odds ratio [OR] = 0.49–0.53) 
were located within 2.5 kb upstream of the CSF1 gene encoding 
M-CSF (Figure  1b), a cytokine promoting macrophage acti-
vation and phagocytosis. The top associated SNP rs1999714 
(OR = 0.49; P = 8.39 × 10–7) was located in the block of linkage 
disequilibrium (LD) of ~2.5 kb, defined by significant r2 >0.5 
LD of surrounding SNPs with rs1999714) close to the CSF1 
gene (Figure 1b). Another top variant, rs12124202 (OR = 0.53; 
P = 7.54  × 10–6), was in the gene enhancer region (position 
GRCh38.p12 chr1: 109 905 601–109 906 901, GeneHancer ID 
GH01J109905), and other SNPs (including rs1999714) were all 
close to the CSF1 regulatory region. However, exploring the im-
pact of these candidate SNPs on gene on gene regulation using a 
number of databases (Supplementary Methods) revealed no ex-
pression quantitative traits for any of the CSF1 SNPs, including 
the SNP in the enhancer region of CSF1. Other susceptibility 
SNPs of potential relevance to Cryptococcus-macrophage inter-
actions included rs6768912 (OR = 1.8; P = 7.56 × 10–6) in the 
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intronic region of NCEH1 (neutral cholesterol ester hydrolase) 
and rs7213159 (OR = 1.9; P = 9.79 × 10–6), a noncoding tran-
script variant of CSNK1D (casein kinase I). NCEH1 encodes 
neutral cholesterol ester hydrolase, an enzyme-removing cho-
lesterol, which plays a pivotal role in antiviral responses (in-
cluding to HIV), in macrophages [20]. Gene silencing of the 
CSNK1D gene has been shown to significantly reduce intracel-
lular mycobacterial load in murine macrophages [21] (Table 2).
To validate findings from our discovery cohort, we per-
formed GWAS in a separate South African cohort of 79 cases 
and 126 controls. The CSF1 SNPs were independently signifi-
cant in this smaller cohort (OR = 0.52–0.63; P < .05) (Table 3). 
In the combined cohort of 319 cases and 399 controls, all 6 CSF1 
SNPs remained significantly associated with cryptococcosis 
susceptibility (Table 3, Figure 1c and d, Supplementary Figure 
2). A meta-analysis of the (nonimputed) genotyped CSF1 SNP 
rs1999713 (present in both discovery and validation cohorts) 
using a fixed-effects allele model generated an OR of 0.53 (95% 
confidence interval [CI], 0.42–0.66, P = 5.96 × 10–8; heteroge-
neity, I2 = 0%, P = .8539) in the combined cohort (Figure 2).
Transcriptomics in Healthy Peripheral Blood Mononuclear Cells and 
Overlap With Genome-Wide Association Study Findings
Using PBMCs from 6 healthy donors of self-identified 
Xhosa ethnicity, we performed RNA-seq after stimula-
tion with heat-killed C neoformans for 24 hours. Compared 
with unstimulated PBMCs, 653 genes were significantly 
up- or down-regulated (fold change >2; adjusted value 
<0.05) (Supplementary Table 1). CSF1 was significantly 
up-regulated (log2-fold change 2.55, adjusted P = 2.6 × 10
–16) 
along with IFN-γ, TNFα, CCL1, and CCL8 (Supplementary 
Table 1). Looking for an overlap between genes differentially 
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Figure 1. Manhattan plots and regional association plots for Discovery (A,B) and Combined (C,D) cohort genome-wide association study. (A) Manhattan plot showing 
the genome-wide P values of association with cryptococcal meningitis in the Discovery cohort. The y-axis represents the log10 P values of single-nucleotide polymorphisms 
(SNPs), and their chromosomal positions are shown on the x-axis. The horizontal blue line shows the significance threshold of P < 1 × 10−4. P values were obtained by logistic 
regression. Six SNPs upstream of the CSF1 gene on chr1 lay above this threshold, including a SNP at the enhancer region of CSF1. (B) Regional association plots at the Chr1 
associated with CSF1 genes. Estimated recombination rates are shown in blue to reflect the local linkage disequilibrium structure around the associated top SNP and its cor-
related proxies, with bright red indicating highly correlated and pale red indicating weakly correlated. (C) Manhattan plot showing the genome-wide P values of association 
with cryptococcosis in the Combined cohort. The horizontal blue line shows the significance threshold of P < 1 × 10−5. The P values were obtained through linear models (lrt) 
in GEMMA software with 15 ancestry principal components as covariates. (D) Regional association plots at the Chr1 CSF1 gene locus.
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expressed in the RNA-seq experiment and genes associated 
with significant SNPs (P < 1 × 10–3) in the GWAS, we found 
38 common genes (Table  4), 9 of which, including CSF1, 
were significantly up-regulated upon cryptococcal stimula-
tion. Genes common to GWAS and RNA-seq were associated 
with functions such as cell adhesion (CD36, CSF1, NRG1, 
and TGFBI), macrophage differentiation (CSF1, IL31RA), cell 
proliferation (RASGRF1, CSF1, NRG1, SPOCK1, and TGFBI), 
and ion transport (ATP6V0D2, CACNA2D3, CTTNBP2, 
KCNJ6, SLC8A1, and SLCO2B1).
Table 2. List of Variants (P < 1.0 × 10−5) Associated With Cryptococcosis in Discovery Cohort
CHR BP SNP Closest Gene Gene Region Minor/Major Frequency Cases/Control P Value OR
1 110450033 rs1999714 CSF1 Upstream gene variant T/G 0.21/0.35 8.4E-07 0.50
110448080 rs12121374 CSF1 Upstream gene variant C/T 0.23/0.36 3E-06 0.52
110449962 rs1999715 CSF1 Upstream gene variant A/C 0.24/0.37 3E-06 0.53
110450177 rs1999713 CSF1 Upstream gene variant C/T 0.24/0.37 4.1E-06 0.53
110448590 rs12124202 CSF1 Enhancer A/G 0.23/0.35 7.5E-06 0.53
210048819 rs2064163 DIEXF Upstream gene variant G/T 0.28/0.42 4.8E-06 0.55
2 788370 rs4854383 AC113607.1 Intronic G/C 0.32/0.20 6.5E-06 1.92
74452327 rs12476235 RP11-287D1.3 Intronic A/G 0.26/0.15 8.4E-06 2.03
74454448 rs60003281 RP11-287D1.3 Intronic C/G 0.26/0.15 9.7E-06 2.01
3 172378536 rs6768912 NCEH1 Intronic A/C 0.5/0.36 7.6E-06 1.78
4 182214247 rs6846320 RP11-665C14.2 Upstream gene variant A/C 0.21/0.10 8.2E-07 2.40
5 78878938 rs12514204 PAPD4 Upstream gene variant C/G 0.51/0.36 2.2E-06 1.83
78881151 rs72635607 PAPD4 Upstream gene variant T/C 0.17/0.29 5.9E-06 0.50
78896859 rs72635609 PAPD4 Upstream gene variant T/G 0.17/0.29 7.5E-06 0.51
78064511 rs10079201 LHFPL2 Upstream gene variant A/G 0.16/0.28 9.1E-06 0.51
7 133876985 rs2068375 LRGUK Intronic T/C 0.03/0.10 6.1E-06 0.28
157726548 rs111508983 PTPRN2 Intronic G/A 0.12/0.04 8.4E-06 3.00
133885512 rs4732006 LRGUK Intronic G/A 0.03/0.10 9.8E-06 0.29
133888726 rs78496580 LRGUK Intronic A/G 0.03/0.10 9.8E-06 0.29
133888979 rs79956644 LRGUK Intronic A/C 0.03/0.10 9.8E-06 0.29
133891059 rs76591747 LRGUK Intronic T/G 0.03/0.10 9.8E-06 0.29
133895592 rs77103757 LRGUK Intronic T/C 0.03/0.10 9.8E-06 0.29
8 567740 rs1703893 ERICH1 Upstream gene variant G/A 0.12/0.22 6.7E-06 0.46
9 92263074 rs78649414 GADD45G intronic C/G 0.07/0.16 5.7E-06 0.39
92258429 rs7025202 GADD45G intronic G/A 0.10/0.20 6.3E-06 0.44
80978737 rs73651328 PSAT1 Upstream gene variant G/A 0.06/0.15 7.3E-06 0.38
92263407 rs74398964 GADD45G Intronic T/C 0.07/0.16 8.4E-06 0.40
92261102 rs80245985 GADD45G Intronic T/C 0.08/0.17 9.9E-06 0.42
13 108504208 rs1396593 FAM155A Intronic A/G 0.10/0.03 2.3E-06 3.70
108505141 rs9520606 FAM155A Intronic T/A 0.10/0.03 2.3E-06 3.70
108506375 rs2136266 FAM155A Intronic T/C 0.10/0.03 2.3E-06 3.70
51950848 rs79789954 INTS6 Intronic T/C 0.08/0.17 2.9E-06 0.40
108503869 rs9520603 FAM155A Intronic A/G 0.10/0.03 3.3E-06 3.48
108503995 rs9520605 FAM155A Intronic C/T 0.12/0.04 3.4E-06 3.12
85474990 rs9602571 RP11-531P20.1 Upstream gene variant A/G 0.09/0.19 3.8E-06 0.42
85475371 rs9602572 RP11-531P20.1 Upstream gene variant G/C 0.09/0.19 3.8E-06 0.42
60084350 rs187657736 RNU7-88P Upstream gene variant T/G 0.10/0.03 3.8E-06 3.62
14 34930846 rs74046057 SPTSSA Intronic T/C 0.53/0.39 4.8E-06 1.78
34930523 rs57186368 SPTSSA Intronic T/C 0.53/0.39 6.5E-06 1.77
34928860 rs12434081 SPTSSA Intronic G/A 0.53/0.39 8.7E-06 1.76
16 85146454 rs75842988 FAM92B Upstream gene variant A/G 0.24/0.12 2.9E-06 2.20
17 5568721 rs115470097 NLRP1 Upstream gene variant G/A 0.18/0.07 1.1E-06 2.64
5568733 rs111541610 NLRP1 Upstream gene variant C/T 0.19/0.09 3.7E-06 2.37
80223048 rs7213159 CSNK1D Intronic C/T 0.32/0.20 9.8E-06 1.89
18 8211568 rs112514564 PTPRM Intronic C/T 0.11/0.03 4.5E-06 3.35
29586237 rs12454708 RNF125 Upstream gene variant C/G 0.03/0.10 6.1E-06 0.28
52320409 rs11877451 C18orf26 Upstream gene variant G/A 0.17/0.28 9.7E-06 0.51
52322820 rs7233418 C18orf26 Upstream gene variant G/C 0.17/0.28 9.7E-06 0.51
20 49810845 rs78757036 AL035457.1 Upstream gene variant A/G 0.08/0.17 5.9E-06 0.41
Abbreviations: BP, base pair; CHR, chromosome; OR, odds ratio; SNP, single-nucleotide polymorphism.
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Gene ontology analysis of differentially expressed genes 
in healthy controls identified enrichment of cytokine ac-
tivity, phagocytosis, complement, and T-cell proliferation 
(Supplementary Table 2). Pathway analysis of these genes 
identified enrichment of cytokine-cytokine receptor inter-
action, complement and coagulation cascades, and Toll-like 
signaling pathways (Supplementary Table 2). These findings 
lend further support to the importance of genes involving 
macrophage activation, differentiation, and phagocytosis, in-
cluding CSF1, to cryptococcal immune responses in the South 
African population.
Functional Characterization in Peripheral Blood Mononuclear Cells From 
Patients With Advanced Human Immunodeficiency Virus
To further examine the importance of M-CSF in cryptococcal 
phagocytosis and killing, we performed ex vivo experiments 
using PBMCs of 5 HIV-infected patients (ART-naive, CD4 
count <200 cells/μL). Exogenous M-CSF significantly improved 
cryptococcal phagocytosis and killing by HIV-infected PBMCs 
(Figure 3). When M-CSF receptors were blocked with specific 
antibodies, phagocytosis and fungal killing were similar to that 
of unstimulated PBMCs, suggesting either incomplete receptor 
block or absence of endogenous M-CSF production in patients 
(Figure 3).
DISCUSSION
Despite bearing the largest infectious disease burden, African 
individuals are underrepresented in studies of disease suscep-
tibility [22]. Globally, fungal infections pose a major threat 
to human health as a result of the expansion of immunosup-
pressive interventions and the ongoing HIV epidemic [23]. 
Due to the challenges in recruiting large enough cohorts, the 
first GWAS in an invasive fungal infection (candidaemia) was 
published in 2014 [24]. The present study is the first to be con-
ducted for cryptococcosis, taking 12 years (2005–2017) to en-
roll a total of 735 patients.
Unlike prior targeted sequencing approaches, we took an 
unbiased, hypothesis-generating approach as used previously 
for candidemia [24, 25], combining GWAS in a clearly defined 
Original
Replication
Fixed eect model
Heterogeneity: I-squared = 0%, tau-squared = 0,
P = .8539
544
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80
562 0.52
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814
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Figure 2. Meta-analysis and forest plot of hard-called genotyped CSF1 single-nucleotide polymorphism rs1999713, present in both discovery and validation cohorts. Model 
shown is allele test under a fixed-effects model (heterogeneity, I2 = 0%, P = .8539). The presence of rs1999713 was associated with an odds ratio (OR) of 0.53 (95% confidence 
interval [CI], 0.42–0.66; P = 5.96 × 10−8) for development of cryptococcosis in the combined cohort.
Table 4. List of GWAS-Identified Genes (Variants With P < .001) Showing 
Differential Expression in the RNA-seq Experiment (Differential Log2 Fold 
Change ≥1) 
Common Genes
Number of Variants 
(P < 1.0 × 10−3) Log2 Fold Change padj
IL31RA 3 3.65 2.5E-26
CSF1 8 2.55 2.6E-16
BCL2L14 2 1.90 3.5E-08
CCL24 1 1.59 0.00242
DPF3 13 1.06 0.02754
SAMD4A 7 1.48 2.8E-05
NDRG2 1 1.41 8.8E-06
HPSE2 2 1.27 0.04782
RASGRF1 1 1.18 0.00489
CD36 2 −1.01 0.03026
C10orf54 2 −1.02 0.00183
NAV1 1 −1.05 0.01309
NAV2 49 −1.06 0.01309
GPR141 1 −1.11 0.02783
INSR 1 −1.21 0.0072
MUC16 1 −1.21 0.0015
HRASLS5 4 −1.27 0.03434
PCSK5 6 −1.27 0.03238
ABCA13 9 −1.28 0.00193
SLC47A1 1 −1.34 0.04405
PXDN 4 −1.35 0.0147
EEPD1 1 −1.40 0.00358
NHSL1 1 −1.43 0.00021
ATP6V0D2 1 −1.46 0.00209
SLC8A1 3 −1.47 0.01127
SPOCK1 2 −1.51 0.00183
EPB41L3 1 −1.54 0.01091
KCNJ6 1 −1.61 6.6E-10
SLCO2B1 1 −1.69 0.00552
NRG1 2 −1.74 0.0002
CTTNBP2 3 −1.82 0.00173
TGFBI 1 −1.97 0.00059
GLIS3 1 −2.03 6E-06
CACNA2D3 1 −2.08 3.6E-06
NCEH1 3 −2.11 6.5E-05
DLEU7 2 −2.20 1E-08
LTBP2 1 −2.47 4.2E-09
PID1 4 −3.06 1.1E-08
Abbreviations: CSF1, colony-stimulating factor 1; GWAS, genome-wide associated study; 
padj, adjusted P value; RNA-seq, ribonucleic acid sequence.
aThe top 9 genes, including CSF1, were significantly up-regulated in response to crypto-
coccal stimulation of peripheral blood mononuclear cells from healthy Xhosa volunteers. 
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case-control cohort, backed up by validation in a second co-
hort, transcriptomics in ethnically matched healthy controls 
and functional studies. Although no individual locus reached 
genome-wide significance, meta-analysis of the nonimputed 
genotyped CSF1 SNP rs1999713 demonstrated P < 10–8 
(OR = 0.53; 95% CI, 0.42–0.66; P = 5.96  ×  10–8) and was in-
dependently significant in both our discovery and validation 
cohorts. It is worth noting that this result was obtained in an 
African population in which GWAS power was limited by ex-
tensive genetic diversity and low linkage disequilibrium [13].
Although no SNPs identified lay within coding regions, we 
identified immunologically plausible upstream genetic variants 
with potential regulatory roles, notably 5 SNPs in the regula-
tory region and 1 SNP on the enhancer region of the CSF1 gene 
encoding M-CSF. Macrophage-CSF induces survival, prolifera-
tion, chemotaxis, differentiation, and activation of monocytes/
macrophages, including microglia [26, 27]. All 6 SNPs were 
confirmed in the validation cohort, remaining significantly as-
sociated with risk of cryptococcosis in the combined cohort. 
Although we did not have CSF1 genotype data for the healthy 
controls to link with gene expression, CSF1 was also one of the 
most highly up-regulated genes upon cryptococcal stimulation 
of PBMCs from healthy, ethnically matched volunteers, and ex-
periments confirmed the importance of M-CSF in uptake and 
killing of Cryptococcus by PBMCs from HIV-infected patients.
Exogenous M-CSF enhances the anticryptococcal activity of 
human monocyte-derived macrophages and enhanced crypto-
coccal killing in a murine model, and it was synergistic with 
fluconazole [28–30]. Macrophage-CSF is one of the principal 
regulators of macrophage function [27, 31], acting as a potent 
proliferation signal, increasing blood and tissue macrophage 
numbers [31–33]. Macrophage-CSF-primed macrophages are 
typically more phagocytic and less competent at antigen pres-
entation, primed to M2 stimuli [32]; however, M-CSF does 
not induce a full M2 phenotype, with M-CSF-primed macro-
phages able to respond to a variety of proinflammatory stimuli 
including IFN-γ and Toll-like receptor activation [31, 32, 34, 
35]. Macrophage-CSF acts synergistically with IFN-γ to drive 
proinflammatory chemokine production including CCL2 
(MCP-1) [31], and it is expressed in a subset of T-cells that also 
express Th1 markers [36]. T-cell derived M-CSF has been shown 
to play a crucial role in the control of bloodborne intracellular 
pathogens [36], and blocking M-CSF increases susceptibility 
to intracellular infections with Listeria and Mycobacterium 
tuberculosis [37, 38]. The exact role of M-CSF in protective 
anticryptococcal immune responses in the context of HIV 
coinfection is unclear, although extensive data demonstrating 
the importance of effective alveolar macrophage responses in 
controlling early cryptococcal infection [6], and the key role of 
circulating and tissue macrophage/microglial responses during 
later disseminated disease [39, 40], provide a plausible basis 
for why variations in CSF1 gene expression might impact sus-
ceptibility to cryptococcal disease. Of interest, the genotyped 
CSF1 SNP rs1999713 is common in different populations, with 
sampled African populations having the lowest MAF at 0.31 
(comparable to 0.34 found in our control group) and East Asian 
populations having the highest MAF at 0.68 (https://gnomad.
broadinstitute.org/).
Searching for inherited immune defects in anticryptococcal 
responses in the context of profound acquired CD4 T-cell de-
pletion might seem paradoxical: yet given only a minority of 
patients with HIV/AIDS develop disseminated cryptococcosis 
despite presumed ubiquitous exposure, such an approach has 
the potential to highlight the contribution of other factors, 
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Figure 3. Cryptococcus internalization and killing by peripheral blood mononuclear cells (PBMCs) from patients with advanced human immunodeficiency virus (HIV) in-
fection (n = 5). The PBMCs were pretreated to block macrophage colony-stimulating factor (MCSF) receptors using α-MCSF or provided with additional MCSF and then 
coinfected with heat-killed cryptococcus. (a) The PBMCs from HIV-infected patients showed significantly higher internalization of Cryptococcus when treated with additional 
MCSF. (b) Human immunodeficiency virus-infected patient PBMCs also exhibit better killing of Cryptococcus compared with the nontreated PBMCs. Phagocytosis and fungal 
killing in anti-MCSF-treated samples were similar to controls, suggesting incomplete receptor block or lack of endogenous MCSF production in patients. For the 5 patients, 
there were 2 technical replicates for the phagocytosis experiments and 3 for the fungal killing experiments: all data points are shown on the graph. P values are shown using 
2-sided t test; box and whiskers plot shows median ± interquartile range.
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including the central role of macrophage phagocytosis and 
killing [41]. Macrophages are also infected by HIV and act as 
its tissue reservoir [42, 43] and are involved in trafficking both 
pathogens to the central nervous system (CNS). We postulate 
that, in the setting of HIV-cryptococcal coinfection, geno-
types rendering macrophages more permissive to uptake and 
intracellular survival of intracellular pathogens are likely to 
confer susceptibility to disseminated cryptococcosis, either 
through direct effects on cryptococcal intracellular burden 
or indirectly through an impact on HIV burden [44]. FcγR 
polymorphisms identified in prior targeted sequencing studies 
[8, 9] could exert an impact through either increasing phago-
cyte cargo (via increased binding and uptake of C neoformans-
immune complexes), shown to be associated with CSF fungal 
burden in HIV-CM [41], and/or increased immune activation 
via antibody-dependent cellular cytotoxicity, leading to disrup-
tion of the blood-brain barrier or CNS tissue injury [9]. Both 
M-CSF and the M-CSF receptor have been proposed as targets 
in the treatment of HIV neurodegenerative disease [45, 46], 
and M-CSF treatments for invasive fungal infections have been 
investigated in animal models [47, 48] and early stage clinical 
trials [49].
Our study had several limitations. The relatively small sample 
size limited our statistical power, and genotype arrays differed 
for the 2 cohorts. The discovery cohort was genotyped on a chip 
biased towards European populations, whereas the validation 
cohort was typed using the newly available global screening 
array ([GSA] containing multiethnic genome-wide content), 
making imputation crucial for analysis of the combined co-
hort. Better designed genotyping chips representing African 
genetic diversity (such as the GSA and newer arrays under de-
velopment) will mean less reliance on imputation methods to 
fill in the gaps in the African genomes. We lacked genotype 
data on the healthy volunteers that would have allowed us to 
examine effects of CSF1 genotype on cytokine expression upon 
cryptococcal stimulation. Furthermore, there was a paucity of 
eQTL data from African populations on the impact of the up-
stream variants identified on CSF1 gene expression and M-CSF 
production: this could be explored in future studies using 
PBMCs of genotyped individuals. Beyond host genotype, other 
unaccounted-for factors, such as those associated with environ-
mental cryptococcal exposure, or concurrent opportunistic in-
fections, may have an impact on cryptococcosis susceptibility.
In any GWAS of infectious disease susceptibility, pathogen 
variation is an additional and usually unaccounted-for element 
[13]. The completion of large, multisite, African phase III trials 
in HIV-associated CM provides the opportunity to undertake a 
larger pan-African GWAS of disease severity and treatment re-
sponse, developing bioinformatic approaches to integrate host 
and pathogen genomics with host CSF immune profiling and 
pathogen virulence phenotyping to determine host and path-
ogen factors underlying poor clinical outcome [2, 50].
CONCLUSIONS
In summary, we have identified and replicated a novel cryp-
tococcosis susceptibility factor in HIV-infected Africans, the 
importance of which was further confirmed through ex vivo 
functional immune studies in patients with advanced HIV as 
well as healthy, ethnically matched controls. Our findings dem-
onstrate that small but well defined GWAS can identify novel 
and immunologically relevant susceptibility loci for an impor-
tant cause of mortality in an African population, provided they 
are replicated and complemented by functional approaches. 
Identifying a high-risk genotype helps elucidate disease mech-
anism and has the potential to identify novel strategies for tar-
geted prevention and host-directed immunotherapy.
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